Xeris Biopharma Holdings, Inc./$XERS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
Ticker
$XERS
Sector
Primary listing
Employees
394
Headquarters
Website
XERS Metrics
BasicAdvanced
$1.3B
-
-$0.21
0.86
-
Price and volume
Market cap
$1.3B
Beta
0.86
52-week high
$8.51
52-week low
$3.59
Average daily volume
2M
Financial strength
Current ratio
1.95
Quick ratio
1.18
Long term debt to equity
-1,300.596
Total debt to equity
-1,332.485
Interest coverage (TTM)
-0.08%
Profitability
EBITDA (TTM)
8.381
Gross margin (TTM)
82.24%
Net profit margin (TTM)
-13.01%
Operating margin (TTM)
-1.51%
Effective tax rate (TTM)
9.41%
Revenue per employee (TTM)
$620,000
Management effectiveness
Return on assets (TTM)
-0.70%
Return on equity (TTM)
165.84%
Valuation
Price to revenue (TTM)
5.085
Price to book
-68.49
Price to tangible book (TTM)
-9.75
Price to free cash flow (TTM)
-74.568
Free cash flow yield (TTM)
-1.34%
Free cash flow per share (TTM)
-0.11
Growth
Revenue change (TTM)
35.62%
Earnings per share change (TTM)
-50.27%
3-year revenue growth (CAGR)
45.50%
3-year earnings per share growth (CAGR)
-43.95%
Bulls say / Bears say
Total revenue for Q2 2025 rose 48.8% year-over-year to a record $71.5 million, prompting Xeris to lift its full-year 2025 revenue forecast to $280–$290 million (Business Wire).
Recorlev net revenue soared 135.7% year-over-year to $31.4 million in Q2, fueled by a 122% jump in patients on therapy, showcasing strong commercial momentum in Xeris’s main growth area (Business Wire).
Xeris spotlighted XP-8121, its Phase 3-ready once-weekly levothyroxine candidate, as a long-term growth driver with potential peak revenue of $1–$3 billion by 2035, extending its growth trajectory beyond the current portfolio (Business Wire).
Keveyis net revenue fell approximately 13% year-over-year in Q2 on lower product shipments, indicating weakness in one of Xeris’s three commercial products (Business Wire).
Xeris’s cash balance declined to $59.3 million at Q2 quarter-end from $71.6 million at year-end 2024, raising concerns over liquidity and potential need for more financing without sustained operating cash flow (Nasdaq).
The company posted a GAAP net loss of $1.9 million (-$0.01 per share) in Q2 2025, further delaying profitability even as adjusted EBITDA improved (Business Wire).
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2025.
XERS News
AllArticlesVideos
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire2 days ago
Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®
Business Wire1 month ago
Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance
Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Xeris Biopharma Holdings, Inc. stock?
Xeris Biopharma Holdings, Inc. (XERS) has a market cap of $1.3B as of October 05, 2025.
What is the P/E ratio for Xeris Biopharma Holdings, Inc. stock?
The price to earnings (P/E) ratio for Xeris Biopharma Holdings, Inc. (XERS) stock is 0 as of October 05, 2025.
Does Xeris Biopharma Holdings, Inc. stock pay dividends?
No, Xeris Biopharma Holdings, Inc. (XERS) stock does not pay dividends to its shareholders as of October 05, 2025.
When is the next Xeris Biopharma Holdings, Inc. dividend payment date?
Xeris Biopharma Holdings, Inc. (XERS) stock does not pay dividends to its shareholders.
What is the beta indicator for Xeris Biopharma Holdings, Inc.?
Xeris Biopharma Holdings, Inc. (XERS) has a beta rating of 0.86. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.